7286-84-2

Usage

Uses

Used in the Plastics Industry:
Vegiben 2E is used as a slip additive for improving the release behavior of polyolefin films and injection-molded products during processing. It reduces friction between the polymer and metal surfaces, leading to enhanced surface quality and appearance of the finished products.
Vegiben 2E is used as a processing aid for increasing the efficiency of the manufacturing process in the plastics industry. It helps in reducing energy consumption and increasing the productivity of the production line, making the production of polyolefin materials more cost-effective and environmentally friendly.

InChI:InChI=1/C8H7Cl2NO2/c1-13-8(12)5-2-4(9)3-6(11)7(5)10/h2-3H,11H2,1H3

Upstream product

• 34408-25-8 methyl 2,5-dichloro-3-nitrobenzoate 
• 88-86-8 2,5-dichloro-3-nitrobenzoic acid 
• 67-56-1 methanol 
• 133-90-4 chloramben 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 863785-96-0 methyl 4-oxo-1H-quinoline-7-carboxylate 
• 1403595-49-2 C₁₃H₁₅Cl₂NO₂ 
• 1403595-48-1 methyl 2,5-dichloro-3-(cyclopentyl(methyl)amino)benzoate 
• 1403595-47-0 methyl 2,5-dichloro-3-(cyclopentylamino)benzoate 
• 230642-89-4 2,5-dichloro-3-(carboxymethyl)benzenesulfinic acid 

Relevant academic research and scientific papers

GLUTAMATE DERIVATIVES OR SALTS THEREOF

Compounds having an excellent CaSR agonist activity are in demand. The invention provides glutamate derivatives or salts thereof, pharmaceutical compositions comprising the glutamate derivatives, preventive or therapeutic agents for diarrhea, hyperparathyroidism or peptic ulcer.

PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY

A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

CASR AGONIST

By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.

ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.

Acyl guanidine sodium/proton exchange inhibitors and method

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure STR1 wherein n is 1 to 5; X is N or C--R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.